Apoptosis News and Research

RSS

Apoptosis is programmed cell death, the body's normal method of disposing of damaged, unwanted, or unneeded cells.

Gene therapies correct three forms of retinal degenerative diseases

Gene therapies developed by University of Pennsylvania School of Veterinary Medicine researchers have worked to correct different forms of blindness. While effective, the downside to these approaches to vision rescue is that each disease requires its own form of gene therapy to correct the particular genetic mutation involved, a time consuming and complex process.

17 Jan 2014

New dye more effective in detecting, measuring cardiolipin in cell membranes

A team that includes Dartmouth College researchers has discovered a new way to detect cardiolipin, a key indicator of heart diseases and some genetic disorders.

16 Jan 2014

Study suggests effective way to counter influenza infections

McGill researchers, led by Dr. Maya Saleh of the Department of Medicine, have identified an enzyme, cIAP2 that helps the lungs protect themselves from the flu by giving them the ability to resist tissue damage. "It's a discovery that offers exciting new avenues for controlling influenza, since until now attempts to target the virus itself have proven challenging, especially in the face of emerging new strains of the virus," says Saleh, who is also a researcher at the Research Institute of the McGill University Health Centre.

15 Jan 2014

Cornell biomedical engineers identify new way to destroy metastasizing cancer cells

Cornell biomedical engineers have discovered a new way to destroy metastasizing cancer cells traveling through the bloodstream - lethal invaders that are linked to almost all cancer deaths - by hitching cancer-killing proteins along for a ride on life-saving white blood cells.

8 Jan 2014

Increased activities of ClC-3 chloride channel may be involved in hippocampal neuronal apoptosis

Over-production of nitric oxide and ion disturbance are involved in neuronal apoptosis around the ischemic area following ischemic brain injury. Prof. Quanzhong Chang and team from Zhuhai Campus of Zunyi Medical College in China established a rat model of hippocampal neuronal apoptosis by using 3-morpholinosyndnomine (SIN-1), a nitric oxide donor.

6 Jan 2014

AstraZeneca to take over Probiodrug's CDK9 inhibitor program

Probiodrug AG announced today the transfer of its experimental cyclin-dependent kinase 9 inhibitor program to AstraZeneca. The transaction includes the sale to AstraZeneca of a lead molecule and back-up compounds with the associated intellectual property. CDK9, which has been implicated in the transcriptional regulation of genes involved in proliferation and inflammation, is a promising target for the treatment of both cancer and inflammatory diseases.

3 Jan 2014

Scientists find inhibiting action of BRD4 protein may eradicate rare type of soft-tissue cancer

A deadly, rare type of soft-tissue cancer may be completely eradicated simply by inhibiting a key protein involved in its growth, UT Southwestern Medical Center researchers report.

27 Dec 2013

Study finds milk serves as protective carrier of bioactive molecules

Polyphenols found in tea manifest anti-cancer effects but their use is limited by poor bioavailability and disagreeable taste. A new study in the Journal of Dairy Science- finds that when epigallocatechin gallate (EGCG), the major extractable polyphenol in green tea and the most biologically active, when diluted in skim milk or other milk complexes remains bioactive and continues to reduce colon cancer cell proliferation in culture at concentrations higher than 0.03 mg of EGCG/mL.

20 Dec 2013

Researchers identify molecular link between liver cancer, obesity, alcoholism, and hepatitis

Obesity, alcoholism, and chronic hepatitis all increase the risk of getting liver cancer, which is the third leading cause of cancer death worldwide. Obesity in particular is driving a significant increase in liver cancer in the United States.

20 Dec 2013

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML).

16 Dec 2013

Experimental drug that targets macrophages decreases cancer's growth

An experimental drug that targets macrophages, a type of immune cells, in the microenvironment surrounding the lethal brain tumor glioblastoma multiforme decreased the cancer's growth and extended survival of laboratory mice with the cancer, scientists will report on Tuesday Dec. 17, at the American Society for Cell Biology annual meeting in New Orleans.

16 Dec 2013

Scientists reveal how two genes interact to kill broad range of cancer cells

Scientists from Virginia Commonwealth University Massey Cancer Center have revealed how two genes interact to kill a wide range of cancer cells. Originally discovered by the study's lead investigator Paul B. Fisher, M.Ph., Ph.D., the genes known as mda-7/IL-24 and SARI could potentially be harnessed to treat both primary and metastatic forms of brain, breast, colon, lung, ovary, prostate, skin and other cancers.

14 Dec 2013

Ribosomal proteins RPL5, RPL11 play essential role in normal cell proliferation

Researchers from the Laboratory of Cancer Metabolism (LCM) led by George Thomas at the Bellvitge Biomedical Research Institute (IDIBELL), the Catalan Institute of Oncology (ICO) and the Division of Hematology/ Oncology, University of Cincinnati, have shown that loss of either one of two tumor suppressors, ribosomal proteins RPL5 or RPL11, fail to induce cell-cycle arrest, but prevent the proliferation of cells as they have a reduced capacity to synthesize proteins.

12 Dec 2013

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

ProNAi Therapeutics, Inc., a leader in developing nucleic acid therapeutics, presented safety and efficacy data from its ongoing Phase II study yesterday at the 55th Annual Meeting of the American Society for Hematology (ASH) in New Orleans, Louisiana.

11 Dec 2013

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics, Inc. today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA™) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013.

11 Dec 2013

Acetylon announces positive preclinical data of ricolinostat (ACY-1215) in models of lymphoma

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, announced that positive preclinical data of selective HDAC6 inhibitor, ricolinostat (ACY-1215), in models of lymphoma were presented today in an oral presentation by Dr. Jennifer Amengual, Assistant Professor of Medicine & Experimental Therapeutics, Columbia University Medical Center.

10 Dec 2013

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops targeted, antibody-based anticancer therapeutics, today announced the first clinical findings with SAR650984 reported in an oral presentation at the ASH annual meeting. The data are from an ongoing Phase I trial assessing this CD38-targeting therapeutic antibody in patients with CD38-positive MM or other hematologic malignancy.

10 Dec 2013

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase inhibitors for enhanced therapeutic outcomes, today announced that positive interim clinical data from the two proof-of-concept clinical trials with selective HDAC6 inhibitor, ricolinostat (ACY-1215), were presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans, LA.

9 Dec 2013

Ligand announces data from preclinical studies on small-molecule oral G-CSF receptor agonist

Ligand Pharmaceuticals Incorporated announced that data from preclinical studies on its granulocyte colony stimulating factor (G-CSF) receptor agonist program were featured in a poster presentation today at the 55th Annual Meeting of the American Society of Hematology in New Orleans.

9 Dec 2013

New study presents promising results for treatment of multiple myeloma

A new study conducted by scientists from the Dana-Farber Cancer Institute at Harvard Medical School, USA, and Karolinska Institutet, Sweden, presents very promising results for the treatment of the cancer form multiple myeloma. The drug candidate used in the research has been developed by scientists from Karolinska Institutet and a Swedish company following its initial identification at the same university. The findings are so promising that the scientists are teaming up with Harvard to bring the drug to clinical trials on patients.

9 Dec 2013

Apoptosis News and Research

Gene therapies correct three forms of retinal degenerative diseases

New dye more effective in detecting, measuring cardiolipin in cell membranes

Study suggests effective way to counter influenza infections

Cornell biomedical engineers identify new way to destroy metastasizing cancer cells

Increased activities of ClC-3 chloride channel may be involved in hippocampal neuronal apoptosis

AstraZeneca to take over Probiodrug's CDK9 inhibitor program

Scientists find inhibiting action of BRD4 protein may eradicate rare type of soft-tissue cancer

Study finds milk serves as protective carrier of bioactive molecules

Researchers identify molecular link between liver cancer, obesity, alcoholism, and hepatitis

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

Experimental drug that targets macrophages decreases cancer's growth

Scientists reveal how two genes interact to kill broad range of cancer cells

Ribosomal proteins RPL5, RPL11 play essential role in normal cell proliferation

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Acetylon announces positive preclinical data of ricolinostat (ACY-1215) in models of lymphoma

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Ligand announces data from preclinical studies on small-molecule oral G-CSF receptor agonist

New study presents promising results for treatment of multiple myeloma

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News